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DIABETIC KIDNEY DISEASE
Diabetic kidney disease (DKD) is the most common cause of
end-stage renal disease (ESRD). The burden of DKD is
expected to continue to increase in parallel with rising preva-
lence of type 2 diabetes and obesity, coupled with the decline
in competing mortality from cardiovascular disease as a re-
sult of more effective therapies [1]. Most patients with DKD
do not undergo renal biopsy and diagnosis is generally based
on clinical parameters, namely presence of diabetes, features
of kidney disease including reduced renal excretory function
and/or albuminuria, and absence of other kidney disease.
However, this pragmatic clinical approach is associated with
some uncertainties. Biopsy studies in people with diabetes
have shown that approximately two-thirds of patients have
superimposed DKD or non-DKD alone and are thereby po-
tentially mismanaged [2]. We know that only a small pro-
portion of patients with diabetes will develop DKD;
moreover, the natural history of the disease is evolving. For
example, a considerable number of patients develop renal
failure without progressing through micro- and macroalbu-
minuric stages, supporting the concept of non-albuminuric
DKD; in addition, patients with microalbuminuria can re-
gress to normoalbuminuria. Histological damage can, how-
ever, be present already at microalbuminuric stages.
DKD is a complex and multifactorial condition determined
by genetic susceptibility and interaction with environmental
factors including glycaemic control, blood pressure and other
risk factors such as smoking and use of nephrotoxic medication.
Therefore, the prediction of an individual’s likelihood to de-
velop DKD, to progress rapidly to ESRD and to respond to
treatment can only be estimated based on features that are
thought to play a universal role in the pathogenesis of DKD. It
is unlikely that therapies which target all pathogenetic princi-
ples simultaneously will ever be available, and personalized
approaches to DKD management are therefore warranted.
However, we do not currently have the evidence base and the
tools to describe individual patients’ disease signature in a man-
ner comparable to rapidly progressing forms of glomerulone-
phritis, vasculitis or in patients receiving renal transplants
where immune diagnostics and molecular pathology inform pa-
tient management.
WHAT IS PROTEOMICS?
Proteomics allows simultaneous quantification of multiple pro-
tein markers in a biosample [3, 4]. These markers can be prede-
fined in targeted proteomic approaches that range from
antibody-based multiplexing platforms to targeted mass spec-
trometry such as multiple reaction monitoring. Such platforms
assess a limited number of proteins with high precision and often
quantitatively. In contrast, untargeted approaches have the po-
tential to assess all proteins in a given sample and are therefore
unbiased; in practice, however, methodological constraints limit
the number of detectable and identifiable features to several
thousands rather than tens of thousands of proteins and modi-
fied proteins in biological material. While traditionally gel-based
techniques have been used in proteomic studies, there is now an
almost exclusive use of mass spectrometry-based methods with
higher resolution and faster sample processing [3, 5].
By detecting the proteins that are actually expressed and pre-
sent in a biological sample, proteomic approaches describe the
current state of a cell, tissue or organism better or at least differ-
ently compared with genomic and transcriptomic experiments.
This is particularly important for dynamic disease processes
and monitoring of response to treatment (Figure 1).
WHICH SAMPLES CAN BE USED FOR
PROTEOMICS?
Tissue samples are thought to provide the best possible infor-
mation on protein expression and the deepest insight into al-
tered physiological processes in a given disease. Newer
proteomic techniques such as matrix-assisted laser desorption/
ionization-imaging mass spectrometry have the potential to be
used for diagnosis [6]. However, in DKD, it is unrealistic to pro-
pose that the number of patients who undergo biopsy will sig-
nificantly increase.
Biofluids including blood can display protein signatures that
derive from specific organs including the kidney and also of
more generic processes such as fibrosis, which is characteristic
not only of advanced renal disease but also of arteriosclerosis or
post-myocardial infarction remodelling. Urine is of interest in
the study of renal diseases as it is obviously produced by the
kidneys. However, protein content is normally low, whereas
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large amounts of protein appear in the urine unselectively in
the event of renal injury as a result of disruption of the glomeru-
lar filtration barrier, tubular secretion or reabsorption. Small
amounts of specific proteins can be masked by more abundant
non-specific proteins such as albumin; this leads to analytical
challenges. Moreover, not all urinary proteins derive from the
kidney (albumin is a prime example), which makes urine an at-
tractive biofluid for proteomic analyses but reduces its specific-
ity to reflect renal diseases. A major advantage of urine,
however, is that it is a rich source of peptides deriving from pro-
tease activity upstream and within the kidney that are relatively
stable once stored in the bladder. Enzymatic protein digestion is
therefore not required in urinary proteomics (more precisely:
peptidomics) and samples can be collected, shipped and stored
without major precautions [7].
A promising alternative to tissue and biofluids that combine
the best of both worlds is the study of extracellular vesicles.
These derive from various cells along the nephron and contain
cell-specific information that can be transferred into target cells.
Their membrane composition and content (cargo) can provide
information about their origin, alterations in the molecular
(proteomic) make-up of source cells and information that
source cells aim to transfer to other cells [8]. Preparation of ex-
tracellular vesicles is, however, challenging and has to follow
agreed protocols to deliver reliable and reproducible results.
WHAT ABOUT ANY PREVIOUS AND
ONGOING PROTEOMIC STUDIES ON DKD?
Urine is the biofluid of choice for proteomic studies in DKD and
has been utilized in studies across the disease spectrum, from
early diagnosis to prediction of renal and other outcomes [9–11].
There are, however, a number of limitations of these studies.
First, due to the costs related to proteomic studies, sample sizes
are often small and data have not always been reproduced in in-
dependent cohorts. Secondly, the technology can be complex and
sometimes proprietary, which limits widespread clinical adoption
of proteomics-based biomarkers. Thirdly, there is no robust gold
standard for the definition of DKD, and it is difficult to assess any
new biomarker against traditional markers such as albuminuria
and renal excretory function with all their limitations.
The most robust data in DKD are available for a classifier
composed of 273 urinary peptides detected by capillary electro-
phoresis coupled to mass spectrometry [12]. The CKD273 clas-
sifier was originally developed as a marker of chronic kidney
disease (CKD), but has shown promise for early diagnosis and
potentially prognosis in DKD. This is plausible since generic
pathways involved in other renal diseases such as inflammation
and altered extracellular matrix remodelling also play a role in
DKD. One could argue that CKD273 represents up to 273 dis-
tinct molecular pathways, whereas in reality many of the pepti-
des of which CKD273 is composed derive from collagens and
most likely reflect alterations in renal fibrosis. Also, the
CKD273 classifier discards thousands of peptides that were not
found to be consistently expressed in urine or to be robustly as-
sociated with CKD. Some of these may be relevant for individ-
ual patients where they indicate patient-specific
pathophysiology but will not be reflected by the CKD273
classifier. Large-scale prospective data on CKD273 will soon be
available from the Proteomic Prediction and Renin
Angiotensin Aldosterone System Inhibition Prevention of Early
Diabetic nephRopathy In TYpe 2 Diabetic Patients With
Normoalbuminuria (PRIORITY) trial where it has been pro-
spectively employed to predict risk of progression from nor-
moalbuminuria to microalbuminuria [13].
Other urine proteomic approaches are limited to small sample
sizes [10, 14] and have not been systematically reproduced. There
are also only very limited data from tissue proteomic studies, most
of which have been conducted in preclinical models [15, 16].
IS THERE A ROLE FOR PROTEOMICS IN
DIABETIC RENAL DISEASE?
The use of proteomics for early diagnosis of DKD is currently
limited by the absence of robust diagnostic criteria. Where pre-
cise technology such as mass spectrometry meets imprecise
clinical disease definitions, it is practically impossible to im-
prove diagnostic accuracy. The same applies to monitoring dis-
ease progression and treatment response, which are currently
assessed by albuminuria and estimated glomerular filtration
rate. To date, there is no guidance on how treatment would
have to be modified in response to changes in proteomic signa-
tures. We believe, however, that post-translational modifica-
tions of proteins, namely glycation, may have a role in DKD
prediction and monitoring of disease progression. Assessment
of variability in glycation pattern is an example of a targeted
mass spectrometry approach that could play a role in clinical
practice in the future [17]. In contrast, the mantra that omics
studies have the potential to unravel new disease pathways and
thereby allow development of novel targeted therapies is partic-
ularly challenging in complex and multifactorial diseases such
as DKD with enormous heterogeneity between patients. There
are very few novel biomarkers for diagnosis and management
of DKD [18], and none of them has been integrated into wide-
spread clinical practice; the bar is high for novel proteomic
biomarkers.
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FIGURE 1: Opportunities for proteomics in the prediction, diagno-
sis and management of people with DKD. While these opportunities
also exist for other biomarkers, proteomic approaches have the po-
tential to cover all aspects of clinical care and offer individual molec-
ular disease characterization and management.
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We therefore see the biggest potential for proteomics in phe-
notyping the molecular basis of an individual’s disease. In other
areas of medicine such as oncology, generations of researchers
have spent enormous effort on histological and molecular de-
scription of different forms of tumours, and the knowledge of
molecular heterogeneity of disease has informed application of
personalized therapeutic approaches. DKD management lags
behind disease management in oncology and in fact other renal
diseases, largely because of the lack of human tissue to support
molecular medicine. Proteomic studies in urine and other bio-
fluids can help to overcome these limitations in DKD.
While efforts to translate existing proteomic data into clini-
cal practice are laudable, we would in parallel like to see more
basic work to develop a disease atlas of DKD describing bio-
marker profiles and molecular signatures in large numbers of
patients. We will very likely see considerable disease heteroge-
neity, but understanding an individual’s molecular pathophysi-
ology will ultimately allow us to target treatments in the spirit
of precision medicine.
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